Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Respiratory

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758052

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758052

Bronchiectasis Drugs

PUBLISHED:
PAGES: 207 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Bronchiectasis Drugs Market to Reach US$1.1 Billion by 2030

The global market for Bronchiectasis Drugs estimated at US$627.1 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$668.7 Million by the end of the analysis period. Growth in the Expectorants segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.9 Million While China is Forecast to Grow at 14.1% CAGR

The Bronchiectasis Drugs market in the U.S. is estimated at US$170.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.0 Million by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Bronchiectasis Drugs Market - Key Trends & Drivers Summarized

Why Is Bronchiectasis Re-Emerging as a Critical Focus in Respiratory Medicine?

Bronchiectasis, once considered an orphan condition, is now gaining renewed attention in respiratory medicine due to a rising global prevalence and increased recognition of its chronic and debilitating nature. Characterized by irreversible bronchial dilation, chronic infection, and excessive mucus production, bronchiectasis significantly impairs lung function and quality of life. Previously thought to be rare and mainly secondary to cystic fibrosis, the condition is now increasingly diagnosed as a standalone non-cystic fibrosis (NCFBE) entity, particularly among older adults and individuals with recurrent respiratory infections. Improved diagnostic capabilities, especially the widespread use of high-resolution CT scans, have contributed to higher detection rates worldwide. The condition’s complex and heterogeneous etiology-ranging from immunodeficiencies and post-infectious damage to autoimmune diseases and chronic aspiration-demands personalized treatment strategies. Despite its rising burden, there is currently no FDA-approved drug specifically indicated for bronchiectasis, making disease management largely symptomatic and reliant on off-label use of antibiotics, anti-inflammatories, bronchodilators, and mucolytics. This therapeutic gap has triggered a significant unmet need in the respiratory drug market and has become a catalyst for research and development efforts focused on targeted therapies. As awareness increases among clinicians and patients, bronchiectasis is transitioning from a neglected disorder to a strategic target for pharmaceutical intervention, prompting the development of new drug classes and novel delivery systems aimed at controlling infection, reducing inflammation, and halting disease progression.

What Therapeutic Approaches Are Gaining Ground in the Bronchiectasis Drug Pipeline?

Current treatment strategies for bronchiectasis primarily focus on controlling infections, managing inflammation, facilitating mucus clearance, and reducing exacerbation frequency. Long-term use of inhaled antibiotics, such as tobramycin and aztreonam, is one of the most widely used options, particularly in patients with chronic Pseudomonas aeruginosa colonization. These inhaled antibiotics help suppress bacterial loads and minimize lung damage over time. However, their off-label use highlights the urgent need for drugs specifically approved for bronchiectasis. Oral macrolides like azithromycin and clarithromycin also serve dual roles as both antibiotics and immunomodulatory agents, reducing exacerbation rates through their anti-inflammatory effects. Nebulized hypertonic saline and mannitol are commonly prescribed mucolytics that improve airway clearance but do not directly address the underlying infection or inflammation. Recent advancements in drug development are exploring novel anti-inflammatory agents, neutrophil elastase inhibitors, and CXCR2 antagonists aimed at disrupting the cycle of infection and inflammation that drives disease progression. Biopharmaceutical companies are also investigating the potential of biologics, such as IL-17 or IL-8 pathway inhibitors, to modulate the immune response in severe or treatment-refractory cases. Additionally, drug-device combination therapies and advanced inhalation technologies are improving drug delivery efficiency to the lower airways, which is crucial given the localized nature of bronchiectatic damage. Several clinical trials are currently in phase II and III stages, assessing the safety and efficacy of novel molecules designed specifically for bronchiectasis patients. These pipeline innovations underscore the ongoing transformation of bronchiectasis from a symptom-managed illness to a pharmacologically addressable disease, bringing hope to millions affected by this chronic respiratory disorder.

How Are Demographic and Epidemiological Shifts Driving Market Demand for Bronchiectasis Drugs?

The demand for bronchiectasis drugs is being significantly shaped by demographic and epidemiological trends, including aging populations, rising chronic respiratory illnesses, and improved diagnostic capabilities. The condition is most prevalent among older adults, and with the global population of individuals over 60 projected to double by 2050, the burden of bronchiectasis is expected to increase correspondingly. In high-income countries, advancements in diagnostic imaging have led to greater identification of previously undiagnosed cases, revealing a higher-than-anticipated prevalence, especially in patients with coexisting conditions like chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis. In lower- and middle-income countries, post-infectious bronchiectasis remains common due to untreated or poorly managed childhood infections like measles, tuberculosis, or pneumonia. Urbanization, air pollution, and smoking are also major contributing factors across both developed and developing regions. Furthermore, increased clinician awareness and improved reporting systems have shed light on the systemic underestimation of this disease's impact on public health. As a result, more patients are entering the healthcare system with chronic respiratory symptoms demanding long-term management. Pharmaceutical companies are now recognizing bronchiectasis as a commercially viable therapeutic target, particularly given the chronic nature of the disease and the high rate of hospitalizations associated with exacerbations. The growing economic and societal burden-measured in terms of healthcare costs, workdays lost, and diminished quality of life-is further prompting governments and health systems to prioritize investment in bronchiectasis care, driving interest in drug development and access expansion.

What Forces Are Propelling Global Market Growth for Bronchiectasis Therapeutics?

The growth in the bronchiectasis drugs market is driven by several factors directly linked to shifting therapeutic paradigms, evolving healthcare priorities, and increased R&D investment in respiratory diseases. Foremost, the lack of approved, disease-specific treatments has created a high-value gap that pharmaceutical companies are racing to fill, leading to an uptick in clinical trial activity and innovation pipelines. The chronic and progressive nature of bronchiectasis makes it a lucrative target for long-term pharmacotherapy, with patients requiring continuous management to control symptoms and prevent exacerbations. Additionally, the growing availability of genetic and biomarker-based profiling is enhancing patient stratification, which supports precision medicine approaches and the development of tailored therapeutics. Advances in inhalation technologies-such as vibrating mesh nebulizers and dry powder inhalers-are improving drug delivery to affected lung regions, increasing efficacy while reducing systemic side effects. Moreover, regulatory agencies are becoming more proactive in encouraging drug development for rare and neglected conditions, offering fast-track designations, orphan drug incentives, and market exclusivity to qualifying bronchiectasis therapies. On the commercial front, pharmaceutical companies are leveraging strategic partnerships with research institutions and biotech firms to accelerate development timelines and share risk. Emerging markets are also presenting new opportunities for market penetration, as healthcare infrastructure improves and respiratory disease awareness spreads. Telehealth, home-based nebulization systems, and digital health integration are further enhancing disease management, allowing patients better access to treatments and increasing adherence. These combined forces-rooted in clinical need, technological capability, and global health policy-are driving the bronchiectasis drugs market into a new era of targeted, patient-focused respiratory care.

SCOPE OF STUDY:

The report analyzes the Bronchiectasis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibiotics, Expectorants, Other Products); Distribution Channel (Online Distribution Channel, Offline Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Akorn Operating Co. LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline plc (GSK)
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Insmed Incorporated
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36428

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bronchiectasis Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Chronic Respiratory Conditions Throws the Spotlight on Bronchiectasis as an Under-Treated Disease
    • Growing Clinical Recognition and Diagnostic Rates Spur Demand for Targeted Bronchiectasis Therapies
    • Here's How Advances in High-Resolution Imaging Are Driving Earlier Diagnosis and Therapeutic Intervention
    • Expansion of the Elderly and Immunocompromised Population Strengthens the Business Case for Long-Term Drug Management
    • Increased Focus on Airway Inflammation and Mucociliary Dysfunction Supports Innovation in Anti-Inflammatory and Mucoactive Drugs
    • Here's the Story: How CF and Non-CF Bronchiectasis Subtypes Are Guiding Precision Drug Development Strategies
    • Rising Use of Real-World Evidence and Biomarker-Based Segmentation Enhances Drug Targeting and Patient Selection
    • Development of Combination Therapies with Bronchodilators and Corticosteroids Drives Portfolio Diversification
    • Global Expansion of Pulmonary Drug Delivery Platforms Supports Innovation in Inhalation-Based Treatment Options
    • Unmet Need for Disease-Modifying Therapies Presents Opportunities for Biologics and Novel Mechanism Agents
    • Increasing Focus on Patient Quality of Life and Symptom Burden Reinforces Market Demand for Long-Term Maintenance Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bronchiectasis Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Expectorants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Expectorants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • JAPAN
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CHINA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • EUROPE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • FRANCE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • GERMANY
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED KINGDOM
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AUSTRALIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • INDIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • LATIN AMERICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MIDDLE EAST
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AFRICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!